Ensysce Biosciences (ENSC) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to 758.68%.
- Ensysce Biosciences' EBIT Margin fell 7775400.0% to 758.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 245.89%, marking a year-over-year decrease of 1031900.0%. This contributed to the annual value of 129.18% for FY2024, which is 3513500.0% up from last year.
- Latest data reveals that Ensysce Biosciences reported EBIT Margin of 758.68% as of Q3 2025, which was down 7775400.0% from 127.64% recorded in Q2 2025.
- In the past 5 years, Ensysce Biosciences' EBIT Margin registered a high of 18.86% during Q3 2024, and its lowest value of 3400.56% during Q2 2022.
- Over the past 5 years, Ensysce Biosciences' median EBIT Margin value was 467.7% (recorded in 2023), while the average stood at 719.09%.
- Per our database at Business Quant, Ensysce Biosciences' EBIT Margin plummeted by -33077400bps in 2022 and then skyrocketed by 29328600bps in 2023.
- Quarter analysis of 5 years shows Ensysce Biosciences' EBIT Margin stood at 122.71% in 2021, then crashed by -253bps to 432.57% in 2022, then tumbled by -42bps to 612.72% in 2023, then skyrocketed by 55bps to 274.34% in 2024, then plummeted by -177bps to 758.68% in 2025.
- Its EBIT Margin stands at 758.68% for Q3 2025, versus 127.64% for Q2 2025 and 149.08% for Q1 2025.